Travere Therapeutics (Travere Therapeutics) Short-Term Capital Lease Obligation : $5.0 Mil (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Short-Term Capital Lease Obligation?

Travere Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5.0 Mil.

Travere Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($4.8 Mil) to Dec. 2023 ($4.9 Mil) and increased from Dec. 2023 ($4.9 Mil) to Mar. 2024 ($5.0 Mil).

Travere Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($3.9 Mil) to Dec. 2022 ($4.4 Mil) and increased from Dec. 2022 ($4.4 Mil) to Dec. 2023 ($4.9 Mil).

Travere Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Travere Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Short-Term Capital Lease Obligation Chart

Travere Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.36

3.91

4.43

4.91

Travere Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.55	4.66	4.78	4.91	5.04

Travere Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Travere Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Travere Therapeutics (Travere Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130

Website

https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Executives

Jula Inrig	officer: Chief Medical Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma	officer: Chief Commercial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote	officer: Senior Vice President, R&D	C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline	officer: Chief Financial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube	director, officer: Chief Executive Officer	3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed	officer: SVP, GC & Corporate Secretary	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin	officer: VP, Corp Controller and CAO	3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague	officer: Chief Financial Officer	370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane	officer: Chief Operating Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole	director	830 WINTER STREET, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066